Key result
ABVD and AVD chemotherapy resolves Hodgkin lymphoma-associated superior vena cava syndrome in a case report.
Why the study?
Hodgkin lymphoma is a rare etiology of superior vena cava syndrome, and the characteristics, management, and prognosis remain unclear.
Case Report (n=1)
Hodgkin lymphoma is a rare cause of SVC syndrome that can be successfully managed with chemotherapy, though it may indicate advanced disease requiring urgent diagnosis and close follow-up.
May support chemotherapy in rare Hodgkin lymphoma-associated SVC syndrome; leaves open optimal regimens and outcomes in larger cohorts.
BACKGROUND Hodgkin lymphoma (HL) is a relatively rare etiology of superior vena cava (SVC) syndrome, with only 24 cases reported in the literature. The characteristics, management, and prognosis of HL-associated SVC syndrome remain unclear. This case report describes nodular sclerosis classical HL and the associated clinical manifestations presenting as SVC syndrome in a middle-aged patient, and it summarizes the characteristics of HL-associated SVC syndrome. CASE REPORT In this case report, we present a 53-year-old Hispanic man with progressively worsening dyspnea, dry cough, facial and neck edema, and dysphagia. SVC syndrome was diagnosed, and pathology revealed nodular sclerosis classical HL. The patient was treated with doxorubicin, bleomycin, vinblastine, and dacarbazine. SVC syndrome improved, and repeated imaging showed that the lymphoma had decreased in size and had become metabolically inactive. CONCLUSIONS We reviewed the characteristics, management, and prognosis of HL-associated SVC syndrome, which may indicate more advanced and recurrent progression in patients with HL. This possibility suggests that physicians should provide urgent diagnosis and closer follow-up, and more aggressive therapies may be needed because of the high risk of recurrence. Therapy may induce late-onset SVC syndrome in patients with HL.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2021) conducted a case report in Hodgkin lymphoma-associated superior vena cava syndrome (n=1). ABVD and AVD chemotherapy was evaluated on Clinical and radiological remission. In a 53-year-old man with Hodgkin lymphoma-associated superior vena cava syndrome, treatment with ABVD and AVD chemotherapy led to clinical improvement and metabolic remission of the lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: